Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:03:52 EDT Thu 31 Oct 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:IMGN
- IMMUNOGEN INC -
http://www.immunogen.com
20:03:52 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
IMGN
- Q
HALTED
31.23
31.25 3.605
Feb 09
Feb 12
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - All 0 today
More trades...
Time ET
Ex
Price
Change
Volume
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-02-12 07:37
U:IMGN
News Release
200
AbbVie Completes Acquisition of ImmunoGen
2024-02-01 16:30
U:IMGN
News Release
200
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 16:30
U:IMGN
News Release
200
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-10 12:00
U:IMGN
News Release
200
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
2023-12-05 06:30
U:IMGN
News Release
200
FDA Grants Priority Review of ImmunoGen ¢ € ™s Supplemental Biologics License Application for ELAHERE ‚ ® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
2023-12-01 16:30
U:IMGN
News Release
200
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-01 13:31
U:IMGN
News Release
200
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROVR, IMGN
2023-11-30 13:46
U:IMGN
News Release
200
INVESTOR ALERT: Weiss Law Investigates ImmunoGen, Inc.
2023-11-30 07:30
U:IMGN
News Release
200
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE ‚ ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
2023-11-02 16:30
U:IMGN
News Release
200
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
2023-11-02 06:30
U:IMGN
News Release
200
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results